News

Oncology nurses can illuminate the potential of avasopasem to enhance pancreatic cancer outcomes and champion ongoing research.

The median overall survival among those treated with tisagenlecleucel was not reached, and the 36-month overall survival rate was 82%.

The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Kim Noonan, DNP, ANP-BC, AOCN, FAAN, said there are things nurses can do to help manage the risk of thrombotic or cardiovascular events.

One patient speaks about her myeloproliferative neoplasm symptoms and how nurses have helped her along the way—despite issues with staffing shortages and high nursing turnover rates.

High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.

A modified dosing schedule may make treatment with ipilimumab plus nivolumab more tolerable for patients with advanced renal cell carcinoma.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.

Olaparib improved survival outcomes in all assessed subgroups of patients with BRCA-altered metastatic castration-resistant prostate cancer.

Amy Martinez, BSN, RN, OCN, explains how her team incorporated the Timed-Up-and-Go test into their workflows on a radiology unit.

Kizzie Charles, MS, APRN, AGCNS-BC, CNOR, walks through the process of developing a successful quality improvement project in the perioperative oncology setting.

New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.

Delivering hazardous drugs safely is complex but essential for the welfare of our health care workers and our patients.

The 3 fundamental coping mechanisms patients should have embedded into their care plan are self-compassion, gratitude, and kindness.

Findings presented at the 2023 San Antonio Breast Cancer Symposium described some possible avenues for artificial intelligence to be useful in breast cancer care.

Most biomarkers in subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p) derived benefit from zanubrutinib vs bendamustine plus rituximab.

The introduction of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma is considered one of the most significant advancements in the past decade.

At a median 39 months of follow-up, zanubrutinib reduced the risk of disease progression by 32% compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

"Differential diagnoses in patients with bicytopenia—particularly those with preserved platelets—are broad and require careful physical examination."

Brexucabtagene autoleucel was associated with a 91% overall response rate among patients with relapsed/refractory mantle cell lymphoma.

Diversity, equity, and inclusion must be a centerpiece of nursing recruitment and retention.

An oncology nurse said he wants patients to tell them about all their symptoms, so that they can get to the root of what is important and plan treatment accordingly.

For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.

During a Case-Based Roundtable™ event, Beth Faiman, Phd, CNP, and participants discussed the use of combination therapies, including daratumumab, as frontline therapy for patients with transplant-ineligible multiple myeloma.

Acalabrutinib, whether as monotherapy or as part of a combination, demonstrated superior progression-free survival outcomes compared to obinutuzumab and chlorambucil.

Patients with multiple myeloma are living longer; therefore, their lifelong treatment expenses can become burdensome.

The overall response rate with ibrutinib plus venetoclax was 82% vs 74% with ibrutinib plus placebo.

The FDA has granted approval to enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

The 4-year progression-free survival rate with daratumumab, bortezomib, lenalidomide, and dexamethasone was 84.3% vs 67.7% with just bortezomib, lenalidomide, and dexamethasone.